We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Demand’s elastic, not fantastic

19 April 2016 By Robert Cyran

Illumina rode the rapidly falling cost of genetic sequencing to a $26 bln valuation as demand bloomed. But a warning of slower growth evaporated almost 25 pct off the stock. Heady multiples only survive if ever cheaper overheads foster ever more uses for a company’s products.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)